Navigation Links
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Date:6/17/2009

the special, whole-person needs of advanced-stage cancer patients. With a network of cancer treatment hospitals and community oncology programs in Illinois, Oklahoma, Pennsylvania and Washington, CTCA encourages patients and their families to participate in treatment decisions with its Patient Empowerment Medicine(SM) model. For more information about Cancer Treatment Centers of America, go to www.cancercenter.com.

About Endocyte

Endocyte is a privately-held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte's advanced proprietary Drug Guidance System (DGS), the Company is working to develop new drugs and diagnostic agents to treat many types of cancer and other serious diseases. The DGS platform makes it possible to use highly-potent drugs on extended and frequent dosing schedules and in combination with other drugs to maximize efficacy. The technology improves drug targeting and reduces the risk of side effects by combining drugs with ligands that are able to identify and attach to receptors found on tumor and other disease cells. Endocyte is currently conducting three separate Phase 2 clinical trials for its lead compound, EC145, together with EC20, a companion molecular imaging agent, for the treatment of ovarian cancer and non-small cell lung cancer. Other clinical-stage products in the Endocyte pipeline include: EC0225, a combination of two potent anticancer drugs; BMS493, a potent drug being developed in partnership with Bristol-Myers Squibb; EC17, a targeted immunotherapy agent; and EC0489, a targeted cancer drug. The Company also has multiple product candidates in pre-clinical stage development.


'/>"/>
SOURCE Cancer Treatment Centers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
3. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
4. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
5. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
6. Advance in Bowel Cancer Test Research
7. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
8. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
9. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
10. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
11. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   InnFocus, Inc ., reported ... the United States for up to 3 years ... Summit in Chicago . The ... of the annual meeting of the American Academy of ... treated approximately 150 glaucoma patients in 6 countries by early ...
(Date:10/17/2014)... , Oct. 17, 2014  China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... the Company has received approval from the China ... manufacturing of human prothrombin complex concentrate ("PCC") at ... Taibang,s new coagulation factor production facility for Good ...
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
Breaking Medicine Technology:InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... May 10, 2011 Cardica, Inc. (Nasdaq: CRDC ... and nine months ended March 31, 2011. Cardica,s management will ... to discuss the financial results and provide an update on ... diligently to bring our first anticipated commercial microcutter device, the ...
... 10, 2011 Cobalis Corp. (CLSC.PK) announced today they ... Allergy Defense Formula , on major national cable and ... featuring leading US allergist Dr. Paul H. Ratner, MD, ... allergies, giving seasonal and year-round sufferers the first truly ...
Cached Medicine Technology:Cardica Announces Fiscal 2011 Third Quarter Financial Results 2Cardica Announces Fiscal 2011 Third Quarter Financial Results 3Cardica Announces Fiscal 2011 Third Quarter Financial Results 4Cardica Announces Fiscal 2011 Third Quarter Financial Results 5Cardica Announces Fiscal 2011 Third Quarter Financial Results 6Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 2Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 3
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Sam Smith as the new Chief Executive Officer of the international ... the International Board of Directors on Tuesday. , ... ... the unanimous confirmation of Sam Smith as the new Chief Executive ...
... Healthcare IT provider grows its operations in the Middle East , ... Systems Corporation (NYSE: PER ) ( www.perotsystems.com ) today ... to manage the pilot deployment of VistA - an open source ... a clinic in the capital, Amman. , ...
... EMPHYSEMA AT RISK FOR OSTEOPOROSIS , New research shows ... includes emphysema and chronic bronchitis, may also be at ... scans and pulmonary function tests on 65 male patients ... compare vertebral bone density with percentage of low attenuation ...
... D. England, MD, Professor and Chairman of Neurology at ... is the principal investigator of two studies recommending ... nerve disorder that to this time had few evidence-based ... two separate papers in the December 3, 2008 online ...
... The American Society of Hematology (ASH) will host its ... Marriott on Thursday, December 4, 2008, beginning at 8:00 ... hematology, the biological sciences, and medical research, is held ... year, students will have the opportunity to explore research ...
... N.J., Dec. 3 MedQuist Inc. (Nasdaq: MEDQ ... world, is pleased to announce the positive resolution of several ... Resolution of the DOJ Investigation , ... an administrative HIPAA subpoena for documents from the United States ...
Cached Medicine News:Health News:New CEO Takes Helm at Mercy Ships 2Health News:New CEO Takes Helm at Mercy Ships 3Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 2Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 3Health News:Journal CHEST: December highlighted studies 2Health News:LSUHSC's England leads development of new testing guidelines for common nerve disorder 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6
... oximeters available, Datex-Ohmeda s TuffSat is the ... transport, and EMS. TuffSat comes fully loaded ... index measurement) a quick, easy-to-use clinical ... perfusion at the sensor site. Now you ...
... A tool for Clinical Professionals and Researchers., ... an easy and efficient way to collect data ... minutes to days at selectable time intervals. With ... straight from the monitor via an interface cable ...
... care challenge., ,The S/5 Critical Care Monitor ... solution for the varying needs of critical care. ... of parameter module options, display and mounting options, ... optimize the bedside set-up to help meet your ...
... modular, easy to use., ,The S/5 ... small-footprint monitor ideally suited for medium care ... modules and Datex-Ohmeda supplies and accessories., ... the same user interface and features as ...
Medicine Products: